Adicet Bio grants new-hire stock options for 725 shares at $7.14 each under inducement plan

By Public Technologies
  • Adicet Bio granted a new-hire non-qualified stock option award on Sept. 30, 2026, covering 725 shares.
  • Exercise price set at USD 7.14 per share, matching the Nasdaq closing price that day.
  • Vesting starts with 25% on the first anniversary of the employee’s start date, then monthly over 36 months to year four.
  • Award issued under the company’s 2022 Inducement Plan, adopted in January 2022, amended in January 2023.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930867520) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.